- Key takeaways
- The three-component ADC system: antibody, linker, and payload
- What conjugation chemistry options are available for commercial ADC manufacturing?
- Drug-to-antibody ratio: the critical quality attribute that defines safety and efficacy
- How does cytotoxic payload handling change the manufacturing facility requirements?
- Downstream processing: purification after conjugation
- What analytical methods characterize DAR distribution and molecular heterogeneity?
Antibody-drug conjugates are deceptively simple in concept: an antibody selectively delivers a cytotoxic payload to cancer cells. Manufacturing them at scale is anything but simple. ADC production requires maintaining GMP-grade antibody manufacturing, handling and conjugating cytotoxic small molecules under strict occupational safety containment, controlling the drug-to-antibody ratio within tight specifications, and characterizing the resulting heterogeneous mixture of conjugated species with analytical methods built specifically for this class.
Key takeaways |
|
|
|
|
|
For the mechanism of action, clinical pipeline, and therapeutic rationale for ADCs, see the related DDN coverage of What are antibody-drug conjugates (ADCs): mechanism, pipeline, and outlook. This article focuses on the manufacturing science that translates that therapeutic potential into a scalable production process. For the parallel manufacturing challenges of bispecific antibodies and other next-generation biologics, see Overcoming production bottlenecks in next-generation biologics.
The three-component ADC system: antibody, linker, and payload
The monoclonal antibody component of an ADC is produced by standard mAb manufacturing: CHO cell culture, Protein A affinity capture, and ion exchange polishing. This upstream component is the most process-mature element of ADC manufacturing, benefiting directly from decades of mAb platform development. The antibody is typically produced and purified to near-drug-substance quality before being subjected to conjugation chemistry, because the conjugation step can affect antibody stability and aggregation, and the final ADC cannot be subjected to the same purification steps as an unmodified antibody. A 2025 comprehensive review of strategic and chemical advances in antibody-drug conjugates confirmed that more than 200 ADC candidates are currently being evaluated in Phase I-III clinical trials, with the ADC market valued at approximately USD 7.82 billion in 2022.
The cytotoxic payload is typically a small molecule with extraordinary potency, selected specifically because it kills cancer cells at nanomolar or picomolar concentrations. Three payload classes dominate approved ADCs: auristatins (MMAE in brentuximab vedotin and polatuzumab vedotin; MMAF in belantamab mafodotin), which inhibit microtubule polymerization; maytansinoids (DM1 in ado-trastuzumab emtansine; DM4 in mirvetuximab soravtansine), which also target tubulin; and topoisomerase inhibitors including the camptothecin derivative DXd used in trastuzumab deruxtecan (Enhertu), which achieved blockbuster commercial status. Each payload class has different chemical reactivity, stability characteristics, linker compatibility, and toxicity profile that constrain the conjugation chemistry options.
The linker connects the antibody and payload and governs the stability of the conjugate in systemic circulation and the mechanism and rate of payload release in the tumor. Cleavable linkers, designed to be cleaved by enzymes or pH conditions specifically in the tumor microenvironment or lysosomes, include protease-sensitive valine-citrulline linkers (used in MMAE-based ADCs), acid-labile hydrazone linkers (used in inotuzumab ozogamicin and gemtuzumab ozogamicin), and redox-responsive disulfide linkers. Non-cleavable linkers, such as the thioether SMCC linker in ado-trastuzumab emtansine, require lysosomal degradation of the entire antibody before the payload is released as a charged metabolite.
What conjugation chemistry options are available for commercial ADC manufacturing?
The choice of conjugation chemistry determines the structural homogeneity of the ADC product, the number and location of payload attachment sites, and the DAR distribution that results from the conjugation reaction. Three distinct approaches to conjugation have been used in approved ADCs, and they differ fundamentally in the control and precision they provide over the attachment reaction.
Strategy | Chemistry | DAR distribution | Site specificity | Homogeneity | Approved examples |
Lysine conjugation | NHS ester reacts with epsilon-amino groups on surface lysine residues; approximately 80 lysines on IgG1 but typically only 10-20 are accessible | DAR 0 to 8 with continuous distribution; many positional isomers at each DAR | Non-specific; any accessible lysine | Low; broad DAR distribution with many regioisomers | Ado-trastuzumab emtansine (Kadcyla); inotuzumab ozogamicin (Besylomab) |
Cysteine conjugation (disulfide reduction) | Partial reduction of interchain disulfide bonds creates free cysteines; maleimide chemistry reacts with free cysteines | DAR 0, 2, 4, 6, 8 (discrete); narrower than lysine; positional isomers within each DAR | Semi-specific; reduced interchain cysteines at approximately 4 to 8 sites on IgG1 | Moderate; narrower DAR distribution than lysine; still heterogeneous within each DAR value | Brentuximab vedotin (Adcetris); polatuzumab vedotin (Polivy); many clinical ADCs |
Site-specific conjugation | Engineered cysteines (ThioMab), unnatural amino acids, enzymatic glycan remodeling (GlycoConnect), or sortase-mediated ligation provide single defined attachment site | Homogeneous DAR 2 or DAR 4; minimal off-target species | Precise; single defined site per antibody or per heavy chain | High; well-defined DAR and single regioisomeric species | Emerging commercial use; multiple site-specific ADCs in Phase II and III clinical development |
The development of site-specific conjugation platforms, including ThioMab technology (engineered cysteine substitution), GlycoConnect (glycan remodeling followed by chemical conjugation), AJICAP, and AbClick, represents the field's response to the manufacturing and pharmacokinetic limitations of heterogeneous conjugation. A 2025 review of chemical evolution in ADC linker design and conjugation strategies confirmed that site-specific platforms enable homogeneous ADCs with controlled DAR and improved safety, attributing the clinical and commercial progress in the field to these conjugation chemistry innovations.
Drug-to-antibody ratio: the critical quality attribute that defines safety and efficacy
The drug-to-antibody ratio is the number of cytotoxic drug molecules attached per antibody molecule in the ADC product. Because conjugation reactions produce a distribution of species with different numbers of attached drugs at different attachment positions, the DAR of a commercial ADC is expressed as an average value over the entire population, and the distribution of DAR species around that average is a separate but equally important quality attribute.
The pharmacological consequences of DAR distribution are well-characterized. Research using CE-SDS to assess the dynamics of conjugational heterogeneity in cysteine-conjugated ADCs demonstrated that the DAR distribution of cysteine-conjugated ADCs is not merely an average value but a dynamic mixture of positional isomers, with different ADC species having different pharmacokinetic profiles and potency. The highly loaded species (DAR 6 and 8) are more hydrophobic, aggregate more readily in solution, and are cleared faster from systemic circulation after dosing, reducing tumor exposure relative to the lower-loaded species. The unconjugated species (DAR 0) contributes no cytotoxic payload but competes with the therapeutic ADC for antigen binding.
The therapeutic window for most cytotoxic payloads is narrow, meaning that modestly elevated systemic exposure produces dose-limiting toxicity. Because DAR directly determines the amount of cytotoxic drug delivered per antibody molecule binding event, and because high-DAR species have faster clearance than expected from antibody PK alone, the DAR distribution is both a quality attribute and a safety attribute that regulatory agencies expect to be tightly controlled and characterized across all development and commercial production lots.
How does cytotoxic payload handling change the manufacturing facility requirements?
The cytotoxic payloads used in ADC manufacturing are designed to kill cancer cells at concentrations that are not far above the concentration that would pose health risks to manufacturing personnel. Auristatins, including MMAE, maytansinoids including DM1, and pyrrolobenzodiazepine (PBD) dimers each have occupational exposure limits that are orders of magnitude lower than standard pharmaceutical manufacturing compounds. PBD dimers, one of the most potent classes of ADC payloads, have OELs in the low nanogram-per-cubic-meter range, requiring engineering controls that prevent atmospheric concentrations above this threshold from reaching operators.
The manufacturing facility requirements that follow from these OEL values include dedicated manufacturing suites with sustained negative air pressure relative to surrounding corridors, which prevents contaminated air from flowing outward during normal operation and process upsets. Vapor-proof containment enclosures with glove ports for manipulation of liquid payload and linker solutions are required at the conjugation step, where the unconjugated payload is present at its highest concentration before purification removes it from the antibody. Environmental monitoring programs must verify that surface contamination and airborne concentration remain below defined action limits, and biological monitoring of operators provides a second layer of health protection.
The facility design requirements for ADC manufacturing have driven the development of a specialized CDMO sector that maintains the combined capabilities of GMP biologic manufacturing for the antibody and highly potent small-molecule synthesis and conjugation. Programs choosing between internal manufacturing and CDMO partnership for ADC production face the capital cost of building or converting dedicated containment suites as a primary decision driver, since the OEL requirements effectively prohibit ADC conjugation in standard pharmaceutical manufacturing areas without significant engineering investment.
Downstream processing: purification after conjugation
The conjugation reaction produces not only the target ADC but several impurities that must be removed before the drug substance meets its release specifications. Unconjugated cytotoxic drug-linker is the most critical impurity because it is both pharmacologically potent and subject to the strictest limit specifications: free drug-linker in the drug substance reaches systemic circulation without the antibody-mediated targeting that limits its distribution to tumor tissue. Aggregates form during the conjugation step when the introduction of hydrophobic payload molecules disrupts antibody solubility and promotes antibody-antibody interactions, particularly for high-DAR species.
Hydrophobic interaction chromatography separates ADC species by DAR because increasing drug loading increases the overall hydrophobicity of the conjugate and therefore its retention on an HIC column under hydrophobic conditions. At the analytical scale, HIC provides the DAR profile of the ADC product, quantifying the relative abundance of each DAR species. At the preparative scale, HIC can be used to enrich specific DAR fractions, removing the lowest-DAR species, which have reduced potency, and the highest-DAR species, which have elevated aggregation and toxicity risk.
Mixed-mode chromatography, which combines hydrophobic and electrostatic interaction mechanisms, provides additional selectivity for ADC polishing steps where standard HIC or ion exchange alone does not achieve the required removal of specific impurities. The mixed-mode selectivity principle relevant to ADC purification is described in the related Separation Science article on Mixed-mode chromatography: tackling challenging impurities.
Final concentration and buffer exchange by tangential flow filtration delivers the ADC drug substance in its formulation buffer. The TFF step for ADC drug substances requires consideration of the hydrophobicity of the conjugated ADC relative to the unconjugated antibody: the TFF membrane should be chosen to minimize non-specific adsorption of the hydrophobic payload to the membrane surface, which can alter DAR by selectively retaining higher-DAR species in the TFF system.
What analytical methods characterize DAR distribution and molecular heterogeneity?
Characterizing the DAR distribution of a heterogeneous ADC requires methods that can distinguish species differing by a single drug molecule of payload, which is typically 700 to 1,000 daltons on an antibody of 150,000 daltons. This mass fraction challenge requires sensitive separation methods rather than simple spectrophotometric average measurements.
Hydrophobic interaction chromatography at the analytical scale is the primary separation-based method for DAR characterization of cysteine-conjugated ADCs. The retention time of each DAR species on an HIC column is proportional to its drug load, allowing the relative abundance of DAR 0, 2, 4, 6, and 8 species to be quantitated from the HIC chromatogram peak areas. This method is validated and widely accepted by regulatory agencies as the primary DAR characterization method, and it is the method used in release testing for most approved cysteine-conjugated ADCs.
Mass spectrometry provides definitive molecular weight confirmation of each DAR species and can distinguish positional isomers that co-elute on HIC. Intact mass analysis under denaturing conditions confirms the mass of each DAR species. Native mass spectrometry under non-denaturing conditions can preserve non-covalent complexes and provide information about the structural integrity of the antibody scaffold after conjugation. Peptide mapping by middle-down or bottom-up approaches localizes each attachment site on the antibody sequence, which is particularly important for site-specific ADCs where confirming selective attachment to the engineered site is a critical quality requirement.
For the full strategic and clinical context of ADCs including the clinical pipeline, approved product profiles, and mechanism of action, see the related DDN article on What are antibody-drug conjugates (ADCs): mechanism, pipeline, and outlook. For the overview of how ADC manufacturing fits within the broader next-generation biologic manufacturing landscape, see Scaling the unscalable: manufacturing cell, gene, and mRNA therapies.
This article was produced under Drug Discovery News' AI Editorial Guidelines.
